Evidence map›Paper›PMID 39589637›Full record

ReviewInternational urology and nephrology2025

Analysis of research trends and hotspots in the primary treatment of end-stage renal disease.

LuYao Shi, Jian Wang, Tao Wei, Zhang Liang, Le Zhang, ChangYan Li, Tao Liu, WenXing Fan, MinZhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

LuYao ShiDepartment of Nephrology, First Affiliated Hospital, Kunming Medical University, No.295, Xichang Road, Kunming, 650032, Yunnan Province, China.
Jian WangDepartment of Nephrology, The Second People's Hospital of Baoshan City, Baoshan, Yunnan Province, China.
Tao WeiLibrary, Kunming Medical University, Kunming, Yunnan Province, China.
Zhang LiangDepartment of Science and Technology, Kunming Medical University, Kunming, Yunnan Province, China.
Le ZhangInstitute for Integrative Genome Biology, University of California Riverside, Riverside, CA, USA.
ChangYan LiDepartment of Nephrology, First Affiliated Hospital, Kunming Medical University, No.295, Xichang Road, Kunming, 650032, Yunnan Province, China.
Tao LiuOrgan Transplantation Center, First Affiliated Hospital, Kunming Medical University, Kunming, Yunnan Province, China.
WenXing FanDepartment of Nephrology, First Affiliated Hospital, Kunming Medical University, No.295, Xichang Road, Kunming, 650032, Yunnan Province, China. fanwx2020@163.com.
MinZhangClinical Pharmacy Center, First Affiliated Hospital, Kunming Medical University, No.295, Xichang Road, Kunming, 650032, Yunnan Province, China. zhangmin800424@163.com.

Funding

535 Talent Project of First Affiliated Hospital of Kunming Medical University 2022535D06Outstanding-Youth Cultivation Project for Union Foundation of Yunnan Applied Basic Research Projects 202201AY070001-044Reserve Talents Project for Young and Middle-aged Academic and Technical Leaders of Yunnan Province 202205AC160062Yunnan Provincial Education Department Scientific Research Fund Project 2024Y229
6 · The paper itself

Abstract

backgroundThere is a lack of bibliometric analysis in research regarding primary therapy for end-stage renal disease (ESRD). This study aims to analyze the literature on ESRD therapy published over the past decade to understand current conditions and study trends for future research.

methodsData were collected from the Web of Science Core Collection (WOSCC) database. Tools like CiteSpace 6.2.R4, 6.1.R6, VOSviewer 1.6.18, and Bibliometrix R4.1.1 were used to reveal research trends and hotspots. In addition, KEGG/GO analysis examined the probable functionalities of genes implicated in ESRD therapy to guide future research.

resultsThe bibliometric analysis presented in this paper indicates that the number of publications has remained relatively stable since 2013. The level of international collaboration is notably high, with the United States serving as the dominant research hub in this field. The University of California system is the most prolific institution, and Transplantation Proceedings is the most frequently published journal in this area. Kalantar-Zadeh, Kamyar is recognized as the most published and cited author. Keywords such as "secondary hyperparathyroidism," "uremic toxins," "cyclosporine," "mycophenolate mofetil," and "biomarkers" have seen a surge in interest recently, reflecting emerging research trends. Furthermore, inflammation and stem cell research have been identified as promising new therapeutic avenues for ESRD.

conclusionThis study identifies major areas, frontiers, and trends in research on primary treatments for ESRD, providing significant implications for future research.

Indexed as

BibliometricsBiomedical ResearchKidney Failure, ChronicHumansBibliometric analysisEnd-stage renal diseaseRenal replacement therapyResearch hotspotsResearch trends

Identifiers

PMID39589637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.